KYMR
KYMR
NASDAQ · Biotechnology

Kymera Therapeutics Inc

$99.45
+9.02 (+9.97%)
As of Jun 22, 9:50 PM ET ·
Financial Highlights (FY 2026)
Revenue
38.18M
Net Income
-303,119,183
Gross Margin
Profit Margin
-794.0%
Rev Growth
-5.8%
D/E Ratio
0.00
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 63.8% 63.8%
Operating Margin -891.1% -802.0% 5.7% 5.2%
Profit Margin -794.0% -754.3% 4.3% 4.5%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 38.18M 40.50M 7.83B 9.20B
Gross Profit 5.00B 5.87B
Operating Income -340,172,593 -324,833,245 447.05M 479.50M
Net Income -303,119,183 -289,450,678 335.40M 415.81M
Gross Margin 63.8% 63.8%
Operating Margin -891.1% -802.0% 5.7% 5.2%
Profit Margin -794.0% -754.3% 4.3% 4.5%
Rev Growth -5.8% -5.8% +18.7% +14.6%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 7.79M 7.79M 1.80B 1.98B
Total Equity 3.71B 3.71B 3.36B 3.32B
D/E Ratio 0.00 0.00 0.53 0.60
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -332,073,852 -334,716,349 592.59M 664.46M
Free Cash Flow 369.62M 455.69M